Neovascular age-related macular degeneration: disease pathogenesis and current state of molecular biomarkers predicting treatment response—a scoping review
Age-related macular degeneration is a major cause of blindness, and the development of anti-vascular endothelial growth factor (VEGF) intravitreal treatments has revolutionised the management of the disease. At the same time, new challenges and unmet needs arose due to the limitations of the current...
Saved in:
Main Authors: | Nikolaos Dervenis, Eleftherios Agorogiannis, Panagiotis Dervenis |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2024-05-01
|
Series: | BMJ Open Ophthalmology |
Online Access: | https://bmjophth.bmj.com/content/9/1/e001516.full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
OCT Biomarkers in Neovascular Age-Related Macular Degeneration: A Narrative Review
by: Cristian Metrangolo, et al.
Published: (2021-01-01) -
Role of ARMS2/HTRA1 risk alleles in the pathogenesis of neovascular age-related macular degeneration
by: Yang Pan, et al.
Published: (2024-12-01) -
Antivascular Endothelial Growth Factor Agents for Neovascular Age-Related Macular Degeneration
by: Ilias Zampros, et al.
Published: (2012-01-01) -
The first experience with brolucizumab for neovascular age-related macular degeneration
by: A.N. Kulikov, et al.
Published: (2022-05-01) -
Dry and neovascular “wet” age-related macular degeneration: Upcoming therapies
by: Audrey Yan, et al.
Published: (2025-01-01)